Why the study?
Non-small cell lung cancer is associated with tumor angiogenesis, and Ang-2 is a potential diagnostic and prognostic marker whose regulatory mechanisms need to be summarized to aid future targeted drug development.
This review summarizes the regulatory mechanisms of Ang-2 in NSCLC, highlighting its potential as a diagnostic biomarker and therapeutic target.
Answers are grounded in this paper and cite their sources.
Ang-2 upregulation may mark aggressive NSCLC biology; leaves open its value as prognostic marker or target.
Non-small cell lung cancer (NSCLC) is one of the malignant tumors with highest mortality in the world, it is still a difficult problem in clinical field. Its occurrence and development are closely associated with tumor angiogenesis. Angiopoietin-2 (Ang-2) is an important angiogenesis factor that has involved in many researches and it has been confirmed that the expression of Ang-2 is significantly up-regulated in tissues and blood of NSCLC. Meanwhile, Ang-2 is related to malignant biological behavior of cancer cells, making it a potential biological marker for the diagnosis and prognosis of NSCLC. At present, researches on Ang-2 how to promote the progression of NSCLC around the world are focused on Ang-2 regulating the proliferation, invasion, and metastasis of NSCLC. This paper summarized and estimated the studies and literature reports of regulatory mechanisms of Ang-2 in NSCLC, hopefully it could help looking for targeted drug treatment of Ang-2 in the future. .
No takes yet. Share an insight, caveat, or question.
Xin et al. (2018) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: